N-methyl-1-(3-methylpyridin-4-yl)methanamine | 915919-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N-methyl-1-(3-methylpyridin-4-yl)methanamine
• CAS: 915919-59-4
• 化学式: C₈H₁₂N₂
• 分子量: 136.19
• InChiKey: RJVPFVJLMPYTBC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  24.9
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• THIAZOLINE AND OXAZOLINE DERIVATIVES AND THEIR METHODS OF USE
  申请人：Faghih Ramin

  公开号：US20080070929A1

  公开（公告）日：2008-03-20

  The invention relates to a series of thiazoline and oxazoline derivatives, compositions thereof, and methods of treating conditions and disorders using such compounds.

  这项发明涉及一系列噻唑啉和噁唑啉衍生物，其组成物和利用这些化合物治疗疾病和疾病的方法。
• BETA-CARBOLINES USEFUL FOR TREATING INFLAMMATORY DISEASE
  申请人：Hepperle Michael E.

  公开号：US20100093713A1

  公开（公告）日：2010-04-15

  This invention provides beta-carboline compounds of formula wherein Ring A is a substituted pyridinyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyrrolidinyl, pyranyl, tetrahydrofuranyl, cyclohexyl, cyclopentyl or thiomorpholinyl ring and R 1 , R 2 and R 3 are as described in the specification. The compounds are IKK-2 inhibitors that are useful for treating IKK-2-mediated diseases such as inflammatory diseases and cancer.

  这项发明提供了式子为的β-咔唑化合物，其中环A是取代的吡啶基、嘧啶基、吗啉基、哌啶基、哌嗪基、吡咯烷基、吡喃基、四氢呋喃基、环己基、环戊基或硫代吗啉基环，而R1、R2和R3如说明书所述。这些化合物是IKK-2抑制剂，可用于治疗IKK-2介导的疾病，如炎症性疾病和癌症。
• Thiazoline and Oxazoline Derivatives and Their Methods of Use
  申请人：Faghih Ramin

  公开号：US20100190776A1

  公开（公告）日：2010-07-29

  The invention relates to a series of thiazoline and oxazoline derivatives, compositions thereof, and methods of treating conditions and disorders using such compounds.

  本发明涉及一系列噻唑啉和噁唑啉衍生物、其组成物以及使用这些化合物治疗病症和疾病的方法。
• AGONISTS OF GPR131 AND USES THEREOF
  申请人：Novack Aaron Robert

  公开号：US20130059856A1

  公开（公告）日：2013-03-07

  Chemical compounds which act as agonists of, or otherwise modulate the activity of, GPR131 are disclosed. Related compositions, formulations and methods of use are also described.

  本文披露了作为GPR131激动剂或其他方式调节其活性的化合物。还描述了相关的组合物、制剂和使用方法。
• NEW COMPOUNDS
  申请人：Engelhardt Harald

  公开号：US20100222331A1

  公开（公告）日：2010-09-02

  The present invention encompasses compounds of general Formula (1) wherein R 2 , R 3 , Q, W, X, Y and Z are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.